Clinical Trial Update: Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a single dose of Exa-cel for severe sickle cell disease (βS/βC genotype) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Exa-cel (exagamglogene autotemcel)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Sickle Cell Disease | Phase 3 | Status: WITHDRAWN